MRS 1523 can exert an antihyperalgesic effect through N-type Ca channel block and action potential inhibition in isolated rat dorsal root ganglion (DRG) neurons. MRS 1523 is an effective and selective adenosine A3 receptor antagonist Ki: 18.9 nM and 113 nM for human and rat A3 receptors, respectively). In rat this corresponds to selectivities of 140- and 18-fold vs A1 and A2A receptors, respectively.

NECA-induced migration is blocked in dose-response fashion by MRS 1523 with calculated Ki of 147 nM[4]. When human endothelial progenitor cells (hEPC) are co-incubated with MRS 1523 (1 nM), a partial blockade of the adenosine-5'-N-ethylcarboxamide (NECA)-induced migration is observed. Furthermore, in 3-days hEPC, the treatment with MRS 1523 100 nM inhibits the NECA-induced migration by 70%. MRS 1523 (0.1-1 μM) treatment obviously antagonizes cell numbers to 40.7% and 57.4% of the control values, respectively, 30 min before the addition of cordycepin (60 μM). MRS1523 (1 μM) alone has any effect on tumor cell growth[3].

Current-clamp recordings demonstrated that neuronal firing of rat DRG neurons was also significantly reduced by A3AR activation in a MRS 1523-sensitive but PD173212-insensitive manner. The endogenous agonist adenosine reduces N-type Ca currents, and its effect is inhibited by 56% in the presence of A3AR antagonist MRS 1523 [2].

212329-37-8

C23H29NO3S

399.55

MRS 1523

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years